(PDF) MDS as a Cause for Prolonged Hematologic Toxicity

MDS as a Cause for Prolonged Hematologic Toxicity After Treatment With Cd19 Targeted Car-T Cell Therapy in Patients With Relapsed Refractory Lymphoma

Hematological Oncology - United Kingdom

doi 10.1002/hon.190_2631

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

June 1, 2019

Authors

Publisher

Wiley

Related search

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

Cancer Research

English

Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology

English

MSKCC Early Experience Using Radiotherapy as a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma Before Cd19 Car T Therapy

Hematological Oncology

Cancer Research

English

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology

Cancer Research

English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology

Cancer Research

English

Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors

Hematological Oncology

Cancer Research

English

CD19-Targeted T Cells for Hematologic Malignancies

Cancer Research

English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology

Cancer Research

English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology

Cancer Research

English